Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

saccharomyces boulardii

What does the research say about saccharomyces boulardii?

9 health outcomes synthesised

Saccharomyces boulardii is a probiotic yeast researched for its effects on digestive health, with syntheses covering 9 health outcomes. The strongest evidence, based on 8 studies, supports its use for reducing diarrhea rates in children with acute diarrhea or Helicobacter pylori infection, typically at doses of 250-1000 mg/day. Research also suggests benefits for reducing diarrhea in clinical populations and improving H. pylori eradication rates, though effects vary by context and population.

Strongest evidence: High-evidence outcomes include reduced diarrhea rate (6 of 8 studies beneficial, large effect size, mainly in children with acute diarrhea or H. pylori infection), reduced diarrhea in clinical populations (8 of 8 beneficial, doses 250–500 mg/day), and improved H. pylori eradication rates (5 of 7 beneficial, small effect, 250 mg twice daily). Moderate-evidence outcomes include reduced duration of diarrhea (3 of 4 beneficial, small-to-moderate effect, in children) and reduced constipation (3 of 3 beneficial, large effect, in H. pylori patients).

Mixed or weaker evidence: Low-evidence outcomes include reduced abdominal distension (3 of 3 beneficial, moderate-to-large effect, primarily in children with H. pylori), reduced abdominal pain (2 of 3 beneficial, mixed effect sizes, in children and adults with H. pylori), and reduced stool frequency (3 of 3 beneficial, moderate effect, in children with acute diarrhea). These conclusions are preliminary due to small study counts (3–4 studies each) and potential publication bias.

Effective dose patterns: Across outcomes, commonly reported doses converge on 250–500 mg/day, with some studies using up to 1000 mg/day. For H. pylori eradication, 250 mg twice daily for 14 days is the only dose explicitly reported. Dosing information was often missing, limiting precise recommendations.

Population insights: Benefits are most consistently demonstrated in children with acute diarrhea or H. pylori infection and in clinical populations (e.g., patients on antibiotics, undergoing radiotherapy, or tube-fed). Generalizability to healthy adults with general diarrhea is uncertain, as two neutral studies (radiotherapy patients, hospitalized adults) suggest the effect may not extend to all populations.

Notable caveats: Publication bias is a recurring concern—null-result studies may be less likely to be published or indexed. The evidence base for several outcomes is small (3–4 studies), and many studies did not specify the form or duration of S. boulardii. Effects may depend on background therapy (e.g., H. pylori regimens) and etiology of diarrhea (e.g., radiation-induced vs. infectious).

Frequently asked

  • What is Saccharomyces boulardii good for according to research?
    Research shows S. boulardii is primarily studied for reducing diarrhea, especially in children with acute diarrhea or gastroenteritis, and in clinical populations (e.g., patients on antibiotics or undergoing H. pylori treatment). There is also evidence for improving H. pylori eradication rates when used alongside standard therapy, and for reducing constipation, abdominal distension, and abdominal pain in patients with H. pylori infection.
  • What dose of Saccharomyces boulardii is typically used in studies?
    The most common doses across studies are 250–500 mg/day, with some studies using up to 1000 mg/day. For H. pylori eradication, 250 mg twice daily for 14 days is a specific reported dose. Dosing information was often not reported, so these ranges reflect typical usage, not a universal recommendation.
  • Who benefits most from Saccharomyces boulardii?
    The strongest evidence supports benefits in children with acute diarrhea or H. pylori infection, and in clinical populations (e.g., patients on antibiotics, with H. pylori, or tube-fed). Benefits in healthy adults with general diarrhea are less established—two neutral studies in radiotherapy and hospitalized adults suggest effects may not be universal.
  • Are there caveats or limitations in the research on Saccharomyces boulardii?
    Yes, publication bias is a major caveat—null results may be underreported. Many studies have small sample sizes and do not report the form or duration of S. boulardii. Several outcomes are supported by only 3–4 studies, making conclusions preliminary. Effects may also depend on the specific population and background therapy used.
  • Does Saccharomyces boulardii help with H. pylori eradication?
    Meta-analyses suggest a small benefit: adding S. boulardii to standard H. pylori therapy increases eradication rates by about 9–12% (risk ratios 1.09–1.14). This evidence is high-strength but limited by heterogeneity across antibiotic regimens and publication bias. One study found no benefit with a vonoprazan-amoxicillin dual regimen, indicating the effect may depend on the background therapy.
  • Is the evidence for Saccharomyces boulardii on abdominal symptoms reliable?
    The evidence for abdominal distension, abdominal pain, and constipation is based on small study sets (3 studies each) and low-to-moderate evidence strength. While all studies show benefits, the small numbers and potential publication bias mean these findings should be considered preliminary. Larger, more diverse trials are needed to confirm these effects.
    Back to top